Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies

Thrombosis and Haemostasis

Volumn 107, Issue 3, 2012, Pages 468-476

  Dienava Verdoold, Ilze ^a   Marchetti, Marina R ^b   te Boome, Liane C J ^c,d   Russo, Laura ^b   Falanga, Anna ^b   Koene, Harry R ^c,e   Mertens, Koen ^a,f   Brinkman, Herm Jan M ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cellular proteases; Coagulation; Platelets; Protein S; Thrombin generation

Indexed keywords

ACTIVATED PROTEIN C; PROTEIN S; THROMBIN;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTHROMBIN TIME; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; WESTERN BLOTTING;

ANTITHROMBIN PROTEINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CATALYTIC DOMAIN; DRUG THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; PEPTIDE FRAGMENTS; PLATELET TRANSFUSION; PROTEIN C; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN S; PROTEOLYSIS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOPENIA;

EID: 84857748253     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-07-0457     Document Type: Article

References (35)

1. Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009; 114: 2307-2314.
2. Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009; 119: 2942-2953.
3. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-132.
4. Mahmoodi BK, Brouwer JL, Veeger NJ, et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-1667.
5. Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 2005; 25: 1311-1320.
6. Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29: 2015-2020.
7. Heeb MJ, Prashun D, Griffin JH, et al. Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J 2009; 23: 2244-2253.
8. Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol 2008; 143: 409-420.
9. Long GL, Lu D, Xie RL, Kalafatis M. Human protein S cleavage and inactivation by coagulation factor Xa. J Biol Chem 1998; 273: 11521-11526.
10. Borgel D, Gaussem P, Garbay C, et al. Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain. Biochem J 2001; 360: 499-506.
11. Heeb MJ, Griffin JH. Activated protein C-dependent and-independent anticoagulant activities of protein S have different structural requirements. Blood Cells Mol Dis 2002; 29: 190-199.
12. Brinkman HJ, Mertens K, van Mourik JA. Proteolytic cleavage of protein S during the hemostatic response. J Thromb Haemost 2005; 3: 2712-2720.
13. Morboeuf O, Borgel D, Gaussem P, et al. Characterization of cleaved plasma protein S with a monoclonal antibody-based assay. Thromb Haemost 2000; 84: 604-610.
14. Oates AM, Salem HH. The binding and regulation of protein S by neutrophils. Blood Coagul Fibrinolysis 1991; 2: 601-607.
15. Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 837-846.
16. Eckle I, Seitz R, Egbring R, et al. Protein S degradation in vitro by neutrophil elastase. Scand J Clin Lab Invest 1993; 53: 281-288.
17. J Mitchell CA, Salem HH. Cleavage of protein S by a platelet membrane protease. J Clin Invest 1987; 79: 374-379.
18. Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112: 4061-4068.
19. Meijer-Huizinga F, Mertens K, van Mourik JA. Isolation and characterization of single-chain protein S. Thromb Haemost 1994; 72: 408-414.
20. Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992; 79: 3203-3211.
21. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
22. Seré KM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. Blood 2004; 104: 3624-3630.
23. Hackeng TM, Hessing M, van 't Veer C, et al. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993; 268: 3993-4000.
24. Hackeng TM, van 't Veer C, Meijers JC, et al. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-21058.
25. Schwarz HP, Heeb MJ, Wencel-Drake JD, Griffin JH. Identification and quantitation of protein S in human platelets. Blood. 1985; 66:1452-1455.
26. Borgel D, Reny JL, Fischelis D, et al. Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolism. Clin Chem 2003; 49: 575-580.
27. Damon AL, Scudder LE, Gnatenko DV, et al. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice. Thromb Haemost. 2008; 100: 1111-1122.
28. Castoldi E, Maurissen LF, Tormene D, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica 2010; 95: 1563-1571.
29. Bertina RM, van Wijngaarden A, Reinalda-Poot J, et al. Determination of plasma protein S, the protein cofactor of activated protein C. Thromb Haemost. 1985; 53: 268-272.
30. Malm K, Dahlbäck B, Arnljots B. Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S. Thromb Haemost. 2003; 90: 227-234.
31. Camire RM, Kalafatis M, Tracy PB. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry 1998; 37: 11896-11906.
32. Gale AJ, Rozenshteyn D. Cathepsin G, a leukocyte protease, activates coagulation factor VIII. Thromb Haemost 2008; 99: 44-51.
33. Plescia J, Altieri DC. Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J 1996; 319: 873-879.
34. Reinhardt C, von Brühl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118: 1110-1122.
35. Nogami K, Ogiwara K, Matsumoto T, et al. Mechanisms of human neutrophil elastase-catalysed inactivation of factor VIII(a). Thromb Haemost 2011; 105: 968-980.